EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

~57 mi. (Shrewsbury, United Kingdom, +10 more cities)

Royal Shrewsbury Hospital

Fallopian Tube Endometrioid Adenocarcinoma, +5 more conditions

NLG207, +1 more drug

chemotherapy, +1 more type

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~68 mi. (Swansea, United Kingdom, +247 more cities)

Local Institution

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

~68 mi. (Swansea, United Kingdom, +174 more cities)

Local Institution

Non-Small Cell Lung Carcinoma

chemoradiotherapy, +3 more drugs

chemotherapy, +2 more types

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~68 mi. (Swansea, United Kingdom, +180 more cities)

Exelixis Clinical Site #194

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~77 mi. (Whitchurch, United Kingdom, +144 more cities)

Velindre Cancer Centre - PPDS

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

~79 mi. (Cardiff, United Kingdom, +201 more cities)

Cardiff & Vale University Health Board /ID# 221236

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

~79 mi. (Cardiff, United Kingdom, +197 more cities)

Cardiff & Vale University Health Board /ID# 215906

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

~79 mi. (Cardiff, United Kingdom, +143 more cities)

Velindre Hospital

RET Mutation

Thyroid Gland Medullary Carcinoma

selpercatinib

targeted therapy

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

~79 mi. (Cardiff, United Kingdom, +97 more cities)

Velindre Cancer Centre

Microsatellite Stable (MSS)

Colorectal Adenocarcinoma

bevacizumab, +2 more drugs

chemotherapy, +1 more type

Study of CPI-0610 in Myelofibrosis (MF)

~79 mi. (Cardiff, United Kingdom, +66 more cities)

University Hospital of Wales

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

pelabresib, +1 more drug

targeted therapy

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

~79 mi. (Cardiff, United Kingdom, +48 more cities)

Cardiff and Vale University Health Board

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +4 more conditions

nanatinostat, +1 more drug

Other, +1 more type

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

~79 mi. (Cardiff, United Kingdom, +45 more cities)

University Hospital of Wales

Multiple Myeloma, +2 more conditions

CC-92480, +1 more drug

hormone therapy, +1 more type